A Phase III Study of Oral Sudapyridine (WX-081) Tablets in Rifampicin-Resistant Pulmonary Tuberculosis Patients (WISH)
A Multicenter, Randomized, Double-Blind, Active-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of Oral Sudapyridine (WX-081) Tablets in Patients With Rifampicin-Resistant Pulmonary Tuberculosis
Sponsor: Shanghai Jiatan Pharmatech Co., Ltd
Listed as NCT05824871, this PHASE3 trial focuses on Rifampin-Resistant Pulmonary Tuberculosis and Tuberculosis, Multidrug-Resistant (MDR-TB) and remains actively recruiting participants. Sponsored by Shanghai Jiatan Pharmatech Co., Ltd, it has been updated 6 times since 2022, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
6 versions recorded-
Jul 2025 — Present [monthly]
Recruiting PHASE3
-
Dec 2024 — Jul 2025 [monthly]
Recruiting PHASE3
Status: Enrolling By Invitation → Recruiting
-
Sep 2024 — Dec 2024 [monthly]
Enrolling By Invitation PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Enrolling By Invitation PHASE3
-
Feb 2024 — Jul 2024 [monthly]
Enrolling By Invitation PHASE3
▶ Show 1 earlier version
-
May 2023 — Feb 2024 [monthly]
Enrolling By Invitation PHASE3
First recorded
Sep 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Shanghai Jiatan Pharmatech Co., Ltd
For direct contact, visit the study record on ClinicalTrials.gov .